72,234 articles
Olof Hammarsten
Olof Hammarsten (1841–1932) was a Swedish physician and chemist, professor of physiological chemistry at Uppsala, who showed casein was the first phosphoprotein and chaired the Nobel chemistry committee.
Olof Nyrén
Olof Nyrén is a Swedish physician and cancer epidemiologist, Professor Emeritus at Karolinska Institutet, known for NEJM studies linking gastroesophageal reflux to esophageal adenocarcinoma and a 1986 trial on non-ulcer dyspepsia.
Olokizumab
Olokizumab (OKZ, CDP6038), a humanized anti-IL-6 monoclonal antibody blocking the gp130 Site 3 epitope, developed by UCB Pharma and R-Pharm, approved in Russia for rheumatoid arthritis.
Olomorasib
Olomorasib (LY3537982), Eli Lilly/Loxo's second-generation covalent KRAS G12C inhibitor, differs from approved sotorasib and adagrasib by nanomolar potency, >90% target occupancy, activity against second-site resistance mutations, and phase 3 SUNRAY trials.
Olopatadine
Olopatadine (KW-4679, AL-4943A), a doxepin analog, is a topical H1 antihistamine and mast cell stabilizer used as eye drops and nasal spray for allergic conjunctivitis and rhinitis; first FDA-approved 1996.
Olorigliflozin
Olorigliflozin (奥洛格列净), brand Dongze'an, is Sunshine Lake Pharma's Class 1 SGLT2 inhibitor capsule (20/50 mg) approved by China's NMPA in January 2026 for type 2 diabetes, alone or with metformin.
Olorofim
Olorofim (F901318), first-in-class orotomide antifungal from F2G, inhibits fungal DHODH in pyrimidine synthesis; active against azole-resistant Aspergillus, Lomentospora, Scedosporium, Coccidioides, inactive against yeasts and Mucorales; oral, phase 2b/3 studied.
Olsalazine
Olsalazine (Dipentum) is an azo-bonded 5-ASA dimer prodrug, US-approved 1987, for maintaining ulcerative colitis remission in sulfasalazine-intolerant adults; 500 mg twice daily, with secretory diarrhea as its distinguishing adverse effect.
Oltipraz
Oltipraz (RP 35972), a synthetic dithiolethione once marketed by Rhone-Poulenc for schistosomiasis, is an Nrf2-activating Phase II enzyme inducer studied as a cancer chemopreventive and NAFLD drug.
Oluf Pedersen (physician-scientist)
Oluf Pedersen, born 1945, is a Danish physician-scientist and professor at the University of Copenhagen known for the Steno-2 trial, which changed type 2 diabetes treatment worldwide, and for gut microbiome research.
Olufunmilayo Olopade
Olufunmilayo Olopade is a Nigerian-born American oncologist and geneticist at the University of Chicago known for research on breast cancer genetics in women of African ancestry.
Olumacostat glasaretil
Olumacostat glasaretil (formerly DRM01) is a topical acetyl-CoA carboxylase inhibitor pro-drug developed by Dermira to cut sebum in acne; Phase 3 trials CLAREOS-1 and CLAREOS-2 missed endpoints in 2018 and development was discontinued.
Olutasidenib
Olutasidenib (Rezlidhia) is an oral mutant IDH1 inhibitor approved by the FDA in December 2022 for relapsed or refractory AML with a susceptible IDH1 mutation, dosed 150 mg twice daily, with 35% CR+CRh and a boxed warning for differentiation syndrome.
Olverembatinib
Olverembatinib (奥雷巴替尼, Henglike, HQP1351, formerly GZD824) is an oral third-generation BCR-ABL1 tyrosine kinase inhibitor for T315I-mutated and TKI-resistant CML, approved in China since November 2021 and in global phase 3 development.
Olvimulogene nanivacirepvec
Olvimulogene nanivacirepvec (Olvi-Vec, GL-ONC1, GLV-1h68) is Genelux's investigational oncolytic vaccinia virus (LIVP strain) with reporter-gene insertions, tested in over 150 patients; lead program is phase 3 ovarian cancer (OnPrime/GOG-3076) plus phase 2 NSCLC.
Omacetaxine mepesuccinate
Omacetaxine mepesuccinate (Synribo), formerly homoharringtonine, is a semisynthetic cephalotaxine protein synthesis inhibitor binding the 80S ribosome, FDA-approved October 26, 2012 for CML resistant or intolerant to two or more tyrosine kinase inhibitors, including T315I-mutant disease.
Omadacycline
Omadacycline (NUZYRA, PTK-0796) is a semisynthetic aminomethylcycline tetracycline antibiotic approved in 2018 for adult CABP and ABSSSI, given once daily orally or intravenously, active against tetracycline-resistant bacteria via C-7/C-9 modifications.
Omalizumab
Omalizumab (Xolair), humanized anti-IgE monoclonal antibody approved 2003 for allergic asthma; later indications include nasal polyps, food allergy (first such drug, 2024), and chronic spontaneous urticaria; boxed anaphylaxis warning; biosimilar Omlyclo approved 2025.
Omar Abdel-Wahab
Omar Abdel-Wahab is a physician-scientist who chairs the Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center and treats leukemia, known for work on RNA splicing mutations and IDH genes in blood cancers.
Omarigliptin
Omarigliptin (MK-3102, MARIZEV) is Merck's once-weekly oral DPP-4 inhibitor for type 2 diabetes, approved in Japan in 2015; 25 mg weekly showed non-inferior HbA1c reduction to daily sitagliptin.
Omaveloxolone
Omaveloxolone (Skyclarys, RTA 408) is a semisynthetic oleanane triterpenoid Nrf2 activator, the first drug approved for Friedreich's ataxia (FDA 2023, EU 2024), dosed 150 mg once daily.
Ombitasvir
Ombitasvir (ABT-267), also in Viekira Pak, Viekirax, and Technivie, is an AbbVie HCV NS5A inhibitor with picomolar, pan-genotypic potency, used with paritaprevir/ritonavir and dasabuvir; EU marketing authorization withdrawn in 2024.
Ombrabulin
Ombrabulin (AVE8062, AC-7700), a Sanofi water-soluble combretastatin A4 analogue vascular disrupting agent, binds endothelial tubulin to collapse tumor vessels; discontinued after failed sarcoma, NSCLC, and ovarian trials.
Omecamtiv mecarbil
Omecamtiv mecarbil (AMG 423, CK-1827452, Kinharto) is a selective cardiac myosin activator for HFrEF that boosts sarcomere contractility without raising calcium or oxygen use; GALACTIC-HF showed HR 0.92, but EMA rejected approval in 2024.
Omega-Atracotoxin
Omega-atracotoxin (ω-ACTX), insect-selective 36–37-residue cystine-knot peptides from Australian funnel-web spider venom (Atrax, Hadronyche) that block insect voltage-gated calcium channels as pore blockers while sparing vertebrate channels; biopesticide leads.
omega-conotoxin GVIA
omega-Conotoxin GVIA is a 27-amino-acid peptide from the venom of the cone snail Conus geographus that blocks N-type calcium channels and has served since the mid-1980s as the standard pharmacological probe for identifying those channels.
Omega−3 fatty acid
Omega-3 fatty acids (ALA, EPA, DHA) are essential polyunsaturated fats, discovered as essential nutrients by the Burrs in 1929; ALA comes from plant oils while EPA and DHA come from seafood, with limited human conversion of ALA to the longer-chain forms.
Omentectomy
Omentectomy is surgery to remove all or part of the greater omentum, the fatty apron of tissue hanging from the stomach, performed mainly during cancer surgery.
Omentopexy
Omentopexy is a surgical technique that mobilizes the greater omentum on its gastroepiploic blood supply and transfers it to cover organs, fill infected spaces, or reinforce repairs.
Omentoplasty
Omentoplasty is a surgical procedure in which the greater omentum is transposed as a vascularized flap to fill defects, control infection, close bronchopleural fistulas, and treat lymphedema.